Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients

被引:72
作者
Goodson, N. J. [1 ,2 ,3 ]
Brookhart, A. M. [2 ]
Symmons, D. P. M. [3 ]
Silman, A. J. [3 ]
Solomon, D. H. [2 ]
机构
[1] Univ Liverpool, Univ Hosp Aintree, Acad Rheumatol Unit, Liverpool L9 7AL, Merseyside, England
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol, Boston, MA USA
[3] Univ Manchester, ARC Epidemiol Unit, Manchester, Lancs, England
关键词
ACUTE MYOCARDIAL-INFARCTION; RHEUMATOID-ARTHRITIS; CYCLO-OXYGENASE-2; INHIBITORS; CYCLOOXYGENASE-2; RISK; EVENTS; POPULATION; ROFECOXIB; DISEASE; METAANALYSIS;
D O I
10.1136/ard.2007.076760
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: There is controversy about the effects of non-steroidal anti-inflammatory drugs ( NSAIDs) on cardiovascular disease (CVD) mortality. The aim of this study was to explore associations between NSAID use and mortality in patients with inflammatory polyarthritis (IP). Subjects and methods: A total of 923 patients with new onset ( IP), recruited to the UK Norfolk Arthritis Register (NOAR) between 1990-1994, were followed up to the end of 2004. Current medication was recorded annually for the first 6 years and then every 2-3 years. Rheumatoid factor (RF) and C-reactive protein (CRP) were measured. Logistic regression was used to calculate all cause and CVD mortality odds ratios ( OR) for NSAID use at baseline and during follow-up, adjusting for gender and time-varying covariates: RF, CRP, joint counts, smoking, steroid use, DMARD use and other medication use. Results: By 2004 there were 203 deaths, 85 due to CVD. At baseline, NSAIDs were used by 66% of patients. In final multivariate models, baseline NSAID use was inversely associated with all cause mortality ( adjusted OR 0.62, 95% CI 0.45 to 0.84) and CVD mortality ( adjusted OR 0.54, 95% CI 0.34 to 0.86). Interval NSAID use had weaker mortality associations: all cause mortality ( adjusted OR 0.72, 95% CI 0.52 to 1.00), CVD mortality ( adjusted hazard ratio (HR) 0.66, 95% CI 0.40 to 1.08). Conclusion: No excess CVD or all cause mortality was observed in NSAID users in this cohort of patients with IP. This is at variance with the literature relating to NSAID use in the general population. It is unclear whether this represents unmeasured confounders influencing a doctor's decision to avoid NSAIDs in the treatment of IP.
引用
收藏
页码:367 / 372
页数:6
相关论文
共 34 条
  • [1] [Anonymous], 1977, INT CLASS DIS
  • [2] The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents
    Armstrong, EP
    Malone, DC
    [J]. CLINICAL THERAPEUTICS, 2003, 25 (01) : 1 - 18
  • [3] Celecoxib for the prevention of sporadic colorectal adenomas
    Bertagnolli, Monica M.
    Eagle, Craig J.
    Zauber, Ann G.
    Redston, Mark
    Solomon, Scott D.
    Kim, KyungMann
    Tang, Jie
    Rosenstein, Rebecca B.
    Wittes, Janet
    Corle, Donald
    Hess, Timothy M.
    Woloj, G. Mabel
    Boisserie, Frederic
    Anderson, William F.
    Viner, Jaye L.
    Bagheri, Donya
    Burn, John
    Chung, Daniel C.
    Dewar, Thomas
    Foley, T. Raymond
    Hoffman, Neville
    Macrae, Finlay
    Pruitt, Ronald E.
    Saltzman, John R.
    Salzberg, Bruce
    Sylwestrowicz, Thomas
    Gordon, Gary B.
    Hawk, Ernest T.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (09) : 873 - 884
  • [4] Nonsteroidal anti-inflammatory drugs and heart failure
    Bleumink, GS
    Feenstra, J
    Sturkenboom, MCJM
    Stricker, BHC
    [J]. DRUGS, 2003, 63 (06) : 525 - 534
  • [5] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
    Bombardier, C
    Laine, L
    Reicin, A
    Shapiro, D
    Burgos-Vargas, R
    Davis, B
    Day, R
    Ferraz, MB
    Hawkey, CJ
    Hochberg, MC
    Kvien, TK
    Schnitzer, TJ
    Weaver, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) : 1520 - 1528
  • [6] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
    Bresalier, RS
    Sandler, RS
    Quan, H
    Bolognese, JA
    Oxenius, B
    Horgan, K
    Lines, C
    Riddell, R
    Morton, D
    Lanas, A
    Konstam, MA
    Baron, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) : 1092 - 1102
  • [7] Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
    Cannon, Christopher P.
    Curtis, Sean P.
    FitzGerald, Garret A.
    Krum, Henry
    Kaur, Amarjot
    Bolognese, James A.
    Reicin, Alise S.
    Bombardier, Claire
    Weinblatt, Michael E.
    van der Heijde, Desiree
    Erdmann, Erland
    Laine, Loren
    [J]. LANCET, 2006, 368 (9549) : 1771 - 1781
  • [8] Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects
    Capone, ML
    Tacconelli, S
    Sciulli, MG
    Grana, M
    Ricciotti, E
    Minuz, P
    Di Gregorio, P
    Merciaro, G
    Patrono, C
    Patrignani, P
    [J]. CIRCULATION, 2004, 109 (12) : 1468 - 1471
  • [9] Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events
    Chan, AT
    Manson, JE
    Albert, CM
    Chae, CU
    Rexrode, KM
    Curhan, GC
    Rimm, EB
    Willett, WC
    Fuchs, CS
    [J]. CIRCULATION, 2006, 113 (12) : 1578 - 1587
  • [10] Methotrexate and mortality in patients with rheumatoid arthritis:: a prospective study
    Choi, HK
    Hernán, MA
    Seeger, JD
    Robins, JM
    Wolfe, F
    [J]. LANCET, 2002, 359 (9313) : 1173 - 1177